Bristol-Myers Squibb (BMS) announced its approximately $74 billion acquisition of Celgene on January 3, 2019, and completed the deal on November 20 that year. Juno Therapeutics was not separately acquired by BMS: Celgene had bought Juno in 2018, so Juno entered BMS through Celgene. The merger put Seattle’s cell-therapy work under a larger corporate owner, but the local employment outlook was uncertain in 2019—and the available reporting does not establish a final Seattle jobs outcome.
What happened in the BMS–Celgene deal?
BMS and Celgene announced a definitive merger agreement on January 3, 2019. The companies described the transaction as worth approximately $74 billion, based on BMS’s January 2 closing share price. That was the deal’s announced valuation, not a current market value.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Biotechnology for Beginners | $28.52 | Buy on Amazon |
| 2 |
|
Biotechnology Demystified | $20.36 | Buy on Amazon |
| 3 |
|
Biotechnology for Beginners | $132.98 | Buy on Amazon |
| 4 |
|
Biotechnology | $101.99 | Buy on Amazon |
| 5 |
|
Superconvergence: How the Genetics, Biotech, and AI Revolutions Will Transform our Lives, Work, and... | $14.80 | Buy on Amazon |
Under the announced terms, each Celgene shareholder was to receive one BMS share, $50 in cash and a tradeable contingent value right (CVR). The CVR could pay an additional $9 if three specified regulatory milestones were met by stated deadlines. BMS and Celgene valued the consideration at $102.43 per Celgene share plus one CVR, using BMS’s January 2, 2019 closing price. BMS’s January 2019 announcement sets out the terms and the company’s strategic rationale.
The transaction closed on November 20, 2019. Celgene became a wholly owned BMS subsidiary, and the closing announcement reiterated the one-share, $50 cash and CVR consideration. BMS’s closing announcement records the completed transaction.
Recommended Free Tools
#1 Best Overall
- New
- Mint Condition
- Dispatch same day for order received before 12 noon
- Guaranteed packaging
- No quibbles returns
How did Juno become part of BMS?
Juno Therapeutics, a cell-therapy company spun out of Fred Hutchinson Cancer Research Center in 2013, had already been acquired by Celgene in 2018. In its 2019 annual report filed with the SEC, Celgene reported approximately $10.4 billion in total consideration for Juno: $9.1 billion for common stock, $966 million for Celgene’s existing investment and $367 million for equity compensation attributable to pre-combination service. Celgene’s SEC-filed annual report gives the breakdown.
That sequence matters: the 2019 BMS–Celgene transaction transferred Celgene and its Juno business into BMS; it was not a separate BMS purchase of Juno. At the time of the merger announcement, GeekWire reported that Juno continued to operate research and development space in Seattle and a manufacturing facility in nearby Bothell.
Rank #2
Why did the merger matter to Seattle biotech?
Seattle had an established Juno footprint
When Juno moved into its custom-built Seattle headquarters in September 2017, it had more than 500 employees, about 350 of them in Seattle, according to GeekWire’s January 2019 report. Those figures describe the company at that time; they are not a later or current staffing count. The combination therefore drew local attention not just as a large corporate deal, but because it involved research and manufacturing operations already rooted in the region.
The company’s stated case focused on pipeline and science
BMS presented the merger as a way to combine complementary oncology and hematology businesses and broaden its pipeline. Its announcement named liso-cel (JCAR017), a CAR T-cell candidate associated with Celgene and Juno, among six potential near-term launches. That list reflected the company’s plans at announcement, not guaranteed launch dates or proof of eventual clinical benefit.
Rank #3
BMS CEO Giovanni Caforio said in the January 2019 announcement: “Together with Celgene, we are creating an innovative biopharma leader, with leading franchises and a deep and broad pipeline that will drive sustainable growth and deliver new options for patients across a range of serious diseases.” At the JP Morgan Global Healthcare Conference, Caforio also told attendees, as quoted by GeekWire: “The deal is really about science, innovation and the pipeline.” Those comments explain the strategic pitch; they do not establish what the merger later delivered.
GeekWire described CAR T as an approach that modifies a patient’s immune cells to attack tumors. The report also noted that some researchers saw potential in combining CAR T therapies with checkpoint inhibitors such as BMS’s Opdivo. That was a scientific possibility discussed at the time, not evidence of a proven benefit for patients or a treatment recommendation.
Rank #4
What was known about Seattle jobs—and what was not?
In January 2019, the effect of the acquisition on Seattle-area employment was unresolved. GeekWire noted that operations at some companies had closed after acquisitions, but it did not report that BMS had announced layoffs or a Seattle closure. Life Science Washington’s then-president, Leslie Alexandre, cautioned against projecting the outcome and pointed to the region’s cellular-therapy research infrastructure as a possible incentive for BMS to maintain immunotherapy activity in Seattle.
The cited reporting does not document a final Seattle headcount or establish that the deal caused a specific number of jobs to be gained or lost. The historical Juno staffing figures are a dated snapshot, not a measure of the merger’s employment effect.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Best Value
What regulatory change accompanied the merger?
As part of the regulatory path to completing the transaction, Celgene agreed to divest its global rights to Otezla to Amgen for $13.4 billion in cash. BMS’s closing announcement describes the divestiture agreement and the deal’s completion. The Federal Trade Commission’s 2019 account also records the Otezla divestiture requirement.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
